Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair.
For one thing, the industry’s top stocks have recovered from lows that stretched into last spring. Blair cited the SPDR S&P Biotech exchange-traded fund (NYSE Arca: XBI), which bounced back from $66.66 a share on April 9, nearly doubling (up 85%) to $123.43 on December 19.
Another reason for optimism, the analysts wrote in a recent report, is better-than-expected policies from President Donald Trump’s second administration—from encouraging the reshoring of biopharma manufacturing in the United States to most favored nation (MFN) pricing, which has spared companies from much-feared tariffs in return for commitments to selling key drugs at lower prices to patients.
“While there are still some unanswered questions regarding drug pricing in the United States, changing frameworks at the FDA, and international threats to the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
